<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H7BB09B672E9F4A3BB14BCDF5B8FA14E0" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 6980 IH: To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6980</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220308">March 8, 2022</action-date><action-desc><sponsor name-id="H001067">Mr. Hudson</sponsor> (for himself and <cosponsor name-id="E000215">Ms. Eshoo</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.</official-title></form><legis-body id="HEB5FB3C514E140C5B72FC05E2D530D6B" style="OLC"><section id="HFB944A6D4DB94FB48C98E8F10DCA7B80" section-type="section-one"><enum>1.</enum><header>Unannounced foreign facility inspections pilot program</header><subsection id="H7D4B7A71B45340E98702BBCD8BF60134"><enum>(a)</enum><header>In general</header><text>The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection. Such pilot program shall evaluate—</text><paragraph id="HED2ECBDFCF3F488DB49B1EBC6D0E5B2B"><enum>(1)</enum><text>differences in the number and type of violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351(a)(2)(B)</external-xref>) identified during unannounced and announced inspections of foreign human drug establishments and any other significant differences between each type of inspection;</text></paragraph><paragraph id="H6BBBAF77474D4C9DA14B92FF11E7E1CA"><enum>(2)</enum><text>costs and benefits associated with conducting announced and unannounced inspections of foreign human drug establishments; </text></paragraph><paragraph id="H123F46CA32094939B2D7FF683FFE835A"><enum>(3)</enum><text>barriers to conducting unannounced inspections of foreign human drug establishments and any challenges to achieving parity between domestic and foreign human drug establishment inspections; and</text></paragraph><paragraph id="HE17A968328924095A0C9C64B6C2A60BF"><enum>(4)</enum><text>approaches for mitigating any negative effects of conducting announced inspections of foreign human drug establishments.</text></paragraph></subsection><subsection id="H260317A8709A4C44B072F35A98094C5E"><enum>(b)</enum><header>Pilot program initiation</header><text>The Secretary shall initiate the pilot program under this section not later than 180 days after the date of enactment of this Act.</text></subsection><subsection id="HE22E48E1D1F8422A9A6F939FDC87F005"><enum>(c)</enum><header>Report</header><text>The Secretary shall, not later than 180 days following the completion of the pilot program, make available on the website of the Food and Drug Administration a final report on the pilot program under this section, including—</text><paragraph id="HE73102773F454A2BA5F305877E9F4FF7"><enum>(1)</enum><text>findings and any associated recommendations with respect to the evaluation under subsection (a), including any recommendations to address identified barriers to conducting unannounced inspections of foreign human drug establishments;</text></paragraph><paragraph id="H69AB60E66EDF4E1EB1C5A13E00C71919"><enum>(2)</enum><text>findings and any associated recommendations regarding how the Secretary may achieve parity between domestic and foreign human drug inspections; and </text></paragraph><paragraph id="H4F4A65C73DE94E6B929CF2F17E436540"><enum>(3)</enum><text>the number of unannounced inspections during the pilot that would not be unannounced under existing practices. </text></paragraph></subsection></section></legis-body></bill> 

